Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients With Limited Stage Small Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy (ADRIATIC)

Next Previous
Trial Profile

A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients With Limited Stage Small Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy (ADRIATIC)

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 12 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
  • Indications Small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms ADRIATIC
  • Sponsors AstraZeneca; AstraZeneca AB

Most Recent Events

  • 30 Apr 2025 Results assessing outcomes by PD-L1 expression in ADRIATIC presented at the 116th Annual Meeting of the American Association for Cancer Research.
  • 10 Apr 2025 Health Canada has granted a Notice of Compliance (NOC) for IMFINZI (durvalumab), as monotherapy, for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) following a priority review of the submission based on results from the pivotal ADRIATIC Phase III trial
  • 17 Mar 2025 According to an AstraZeneca media release, the European Union (EU) has approved Imfinzi (durvalumab) as monotherapy for the treatment of adults with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following platinum-based chemoradiation therapy (CRT),The approval is based on results from this trial.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top